Product Description
Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins.
Mechanisms of Action: GAL3 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galectin
Company Location: NORCROSS GA 30071
Company CEO: Joel Lewis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Germany, Poland, Spain
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Galectin presented P2 Hypertension, Portal results on 2025-11-10 for Belapectin
- Clinical Outcomes Reported - Galectin presented P3 Non-alcoholic Steatohepatitis results on 2025-11-10 for Belapectin
- Clinical Outcomes Reported - Galectin presented P2 Non-alcoholic Steatohepatitis results on 2025-05-12 for Belapectin
Highest Development Phases
Phase 3: Liver Cirrhosis|Non-alcoholic Steatohepatitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-512619-28-00 |
GT-031 | P3 |
Completed |
Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2025-02-18 |
2025-05-02 |